150 related articles for article (PubMed ID: 32447118)
1. EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.
Martins-Filho SN; Weiss J; Pham NA; Li Q; Cabanero M; Fares A; Stewart EL; Shi R; Patel D; Pal P; McConnell J; Bradbury PA; Sacher AG; Leighl NB; Grindlay A; Allison F; Li M; Yasufuku K; Shepherd FA; Moghal N; Tsao MS; Liu G
Lung Cancer; 2020 Jul; 145():144-151. PubMed ID: 32447118
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
3. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
Chen Y; Zhang R; Wang L; Correa AM; Pataer A; Xu Y; Zhang X; Ren C; Wu S; Meng QH; Fujimoto J; Jensen VB; Antonoff MB; Hofstetter WL; Mehran RJ; Pisimisis G; Rice DC; Sepesi B; Vaporciyan AA; Walsh GL; Swisher SG; Roth JA; Heymach JV; Fang B
Cancer; 2019 Nov; 125(21):3738-3748. PubMed ID: 31287557
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
[TBL] [Abstract][Full Text] [Related]
8. Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma.
Zhao J; Shao J; Zhao R; Li R; Yu K; Zhu L; Zhang J
Thorac Cancer; 2018 Jan; 9(1):129-135. PubMed ID: 29120087
[TBL] [Abstract][Full Text] [Related]
9. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
11. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
[TBL] [Abstract][Full Text] [Related]
12. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
13. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
14. Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
Jukna A; Montanari G; Mengoli MC; Cavazza A; Covi M; Barbieri F; Bertolini F; Rossi G
J Thorac Oncol; 2016 Apr; 11(4):e49-51. PubMed ID: 26746366
[TBL] [Abstract][Full Text] [Related]
15. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Pham NA; Radulovich N; Ibrahimov E; Martins-Filho SN; Li Q; Pintilie M; Weiss J; Raghavan V; Cabanero M; Denroche RE; Wilson JM; Metran-Nascente C; Borgida A; Hutchinson S; Dodd A; Begora M; Chadwick D; Serra S; Knox JJ; Gallinger S; Hedley DW; Muthuswamy L; Tsao MS
Sci Rep; 2021 May; 11(1):10619. PubMed ID: 34011980
[TBL] [Abstract][Full Text] [Related]
17. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
18. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Venugopalan A; Lee MJ; Niu G; Medina-Echeverz J; Tomita Y; Lizak MJ; Cultraro CM; Simpson RM; Chen X; Trepel JB; Guha U
Oncotarget; 2016 Aug; 7(34):54137-54156. PubMed ID: 27494838
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
[TBL] [Abstract][Full Text] [Related]
20. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
